Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYC065 and Venetoclax for Relapsed or Refractory CLL
NCT03739554Phase 1Completed
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Jan 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fadraciclib in chronic lymphocytic leukemia (CLL), sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoint: Number of patients who experience dose-limiting toxicity. Started Jan 2019; status: completed.
02
Drugs
fadraciclib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT03739554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739554.